MannKind 
Welcome,         Profile    Billing    Logout  
 5 Products   98 Diseases   5 Products   8 Trials   722 News 


«1234»
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Clinical, Journal:  Recent avenues in Novel Patient-Friendly Techniques for the Treatment of Diabetes. (Pubmed Central) -  Dec 18, 2020   
    Such results call for more potential work to develop a promising system. The novel approaches range from the delivery of non-insulin blood glucose lowering agents to insulin-based therapy with minimal invasion are highly desirable.
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Clinical, Review, Journal, Adverse events:  Comprehensive Pulmonary Safety Review of Inhaled Technosphere Insulin in Patients with Diabetes Mellitus. (Pubmed Central) -  Dec 16, 2020   
    The novel approaches range from the delivery of non-insulin blood glucose lowering agents to insulin-based therapy with minimal invasion are highly desirable. Pulmonary safety assessment of the TI inhalation system did not identify any safety issues in individuals with either T1DM or T2DM.
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Afrezza Safety and Pharmacokinetics Study in Pediatric Patients (clinicaltrials.gov) -  Sep 17, 2020   
    P2,  N=30, Completed, 
    However, given the adverse effects, more effective strategies are needed to maintain these therapeutic regimens. Recruiting --> Completed | N=46 --> 30 | Trial completion date: Jan 2021 --> Jun 2020 | Trial primary completion date: Jul 2020 --> Mar 2020
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Trial completion, Trial completion date, Trial primary completion date:  Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients (clinicaltrials.gov) -  Sep 14, 2020   
    P3,  N=28, Completed, 
    Recruiting --> Completed | N=46 --> 30 | Trial completion date: Jan 2021 --> Jun 2020 | Trial primary completion date: Jul 2020 --> Mar 2020 Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Jun 2020 | Trial primary completion date: Sep 2020 --> Jun 2020
  • ||||||||||  clofazimine inhalational (QRM-003) / Qrum Pharma, Lamprene (clofazimine) / Novartis
    [VIRTUAL] Single and Repeated Dose Pharmacokinetics of QRM-003 in Rodent Models (ATS 2020 Virtual) -  Jul 6, 2020 - Abstract #ATSI2020ATS-I_1374;    
    We anticipate that the pulmonary retention of clofazimine following inhalation will result in lower extrapulmonary tissue accumulation, i.e. subcutaneous fat and small intestinal tissue, which are the main sites of clofazimine adverse events. Additional studies are ongoing to evaluate drug distribution to these tissues following inhaled delivery, and to compare extrapulmonary exposure following oral vs. inhaled clofazimine delivery.
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    [VIRTUAL] Inhaled and Background Basal Insulins Improved A1C and QoL Subdomains in Patients with Type 2 Diabetes: An Observational Study () -  May 18, 2020 - Abstract #ADA2020ADA_1801;    
    Rapid-acting inhaled (Afrezza) and injected mealtime insulins are available for patients with type 2 diabetes who are also treated with basal insulin...Although this interim analysis did not achieve its primary endpoint of significant increase of time spent in glycemic goal range, possibly caused by patients not self-adjusting post-prandial dosing as instructed. Patients treated with inhaled insulin with background basal insulin for 14 weeks experienced significant reduction of A1c and significant improvements of Useful, Freeing, and Difficult QoL subdomains compared to baseline.
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Clinical, Journal:  Case Report: Efficient Avoidance of Hospitalization for Diabetic Ketosis Utilizing Technosphere Inhaled Insulin. (Pubmed Central) -  Apr 11, 2020   
    Technosphere inhaled insulin (TI) may be an alternative to subcutaneously injected fast-acting insulins, not only because of its rapid onset of action but also lack of stacking leading to late-onset hypoglycemia. In conclusion, TI may well be more efficacious and safer in the outpatient management of diabetic ketosis/ketoacidosis than standard subcutaneously injected rapid-acting insulin.
  • ||||||||||  clofazimine inhalational (QRM-003) / Qrum Pharma, Lamprene (clofazimine) / Novartis
    Single and Repeated Dose Pharmacokinetics of QRM-003 in Rodent Models (PENNSYLVANIA CONVENTION CENTER, Room 113 B-C (100 Level)) -  Mar 15, 2020 - Abstract #ATS2020ATS_3431;    
    We anticipate that the pulmonary retention of clofazimine following inhalation will result in lower extrapulmonary tissue accumulation, i.e. subcutaneous fat and small intestinal tissue, which are the main sites of clofazimine adverse events. Additional studies are ongoing to evaluate drug distribution to these tissues following inhaled delivery, and to compare extrapulmonary exposure following oral vs.
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Journal:  Technosphere Insulin-Induced Pulmonary Infiltrate. (Pubmed Central) -  Mar 10, 2020   
    Additional studies are ongoing to evaluate drug distribution to these tissues following inhaled delivery, and to compare extrapulmonary exposure following oral vs. No abstract available
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    #Afrezza (Twitter) -  Mar 6, 2020   
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Afrezza (Twitter) -  Feb 9, 2020   
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Enrollment closed, Trial primary completion date:  A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza (clinicaltrials.gov) -  Jan 29, 2020   
    P4,  N=29, Active, not recruiting, 
    No abstract available Recruiting --> Active, not recruiting | Trial primary completion date: Nov 2019 --> Mar 2020